Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

OLATOYOSI M ODENIKE

Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology

NPI
1194887646
CMS profile
99079
Location
CHICAGO, IL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2019 · Entire year

$4,975.41

13 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2019 · entire year · sorted by reported total

Nature of paymentAmountRecords
Consulting Fee $3,390.00 1
Travel and Lodging $1,090.90 5
Food and Beverage $494.51 7

By paying entity

PY2019 · entire year · sorted by reported total

Paying entityAmountRecords
Celgene Corporation $3,516.65 3
AbbVie, Inc. $1,209.53 7
Novartis Pharmaceuticals Corporation $135.00 1
Taiho Oncology, Inc. $100.84 1
JAZZ PHARMACEUTICALS INC. $13.39 1

Page 1 of 1; records 1–13 of 13 matching records. This page contains 13 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

OLATOYOSI M ODENIKE

NPI 1194887646 · CMS profile ID 99079

Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology

CHICAGO, IL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–13 of 13 matching records. This page contains 13 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1194887646?year=2019&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
OLATOYOSI M ODENIKE, NPI 1194887646, CMS profile ID 99079. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–13 of 13 matching records. This page contains 13 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1194887646?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
APA 7
IndustryPayments. (2026). OLATOYOSI M ODENIKE, NPI 1194887646, CMS profile ID 99079. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–13 of 13 matching records. This page contains 13 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1194887646?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
Bluebook
OLATOYOSI M ODENIKE, NPI 1194887646, CMS profile ID 99079, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–13 of 13 matching records. This page contains 13 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1194887646?year=2019&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30

13 matching records · $4,975.41 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 13 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–13 of 13.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Taiho Oncology, Inc. $100.8412/07/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 679425331 CMS
AbbVie, Inc. $239.9610/22/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 647893785 CMS
AbbVie, Inc. $43.0010/22/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 647893787 CMS
AbbVie, Inc. $28.4710/22/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 647893789 CMS
AbbVie, Inc. $170.0010/22/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 647893791 CMS
AbbVie, Inc. $64.2310/22/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 647893797 CMS
AbbVie, Inc. $214.0010/21/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 647893793 CMS
AbbVie, Inc. $449.8710/21/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 647893795 CMS
Novartis Pharmaceuticals Corporation $135.0006/18/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659894551 CMS
Celgene Corporation $3,390.0005/21/2019 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673018151 CMS
Celgene Corporation $109.5805/16/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672861393 CMS
Celgene Corporation $17.0705/16/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672863499 CMS
JAZZ PHARMACEUTICALS INC. $13.3904/27/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 684178899 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $4,975.41 13
PY2020 $8,990.00 3
PY2021 $11,923.60 10
PY2023 $16,954.12 16
PY2024 $3,862.50 4
PY2025 $4,631.25 2

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2023, 2024, 2025
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2023 , PY2024 , PY2025
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $136,498.65 16
PY2024 Recipient $579.84 2
PY2024 Principal investigator $57,505.53 9
PY2023 Principal investigator $540,389.47 36
PY2022 Principal investigator $455,007.19 49
PY2021 Principal investigator $651,058.16 62
PY2020 Recipient $3,300.00 1
PY2020 Principal investigator $749,494.38 87
PY2019 Principal investigator $687,194.48 104

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2020

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

88 records in PY2020

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Otsuka Pharmaceutical Co., Ltd. $10,698.80 12/29/2020 Non-covered Recipient Entity
THE UNIVERSITY OF CHICAGO
AN OPEN-LABEL, MULTICENTER, EXTENSION STUDY FOR SUBJECTS WHO PARTICIPATED IN PRIOR CLINICAL STUDIES OF ASTX727 (STANDARD DOSE) No dispute reported 06/30/2026 753392963
Principal investigator 1 AbbVie Inc. $19,227.99 12/21/2020 Non-covered Recipient Entity
DCAM OUTPATIENT PHARMACY
M16-415 No dispute reported 06/30/2026 721201415
Principal investigator 1 Otsuka Pharmaceutical Co., Ltd. $1,520.00 12/17/2020 Non-covered Recipient Entity
THE UNIVERSITY OF CHICAGO
A PHASE1-2 PHARMACOKINETIC GUIDED DOSE-ESCALATION AND DOSE-CONFIRMATION STUDY OF ASTX727, A COMBINATION OF THE ORAL CYTIDINE DEAMINASE INHIBITOR (CDAI) E7727 WITH ORAL DECITABINE IN SUBJECTS WITH MYELODYSPLASTIC SYNDROMES (MDS) No dispute reported 06/30/2026 753392959
Principal investigator 1 Otsuka Pharmaceutical Co., Ltd. $55,577.60 12/17/2020 Non-covered Recipient Entity
THE UNIVERSITY OF CHICAGO
A PHASE1-2 PHARMACOKINETIC GUIDED DOSE-ESCALATION AND DOSE-CONFIRMATION STUDY OF ASTX727, A COMBINATION OF THE ORAL CYTIDINE DEAMINASE INHIBITOR (CDAI) E7727 WITH ORAL DECITABINE IN SUBJECTS WITH MYELODYSPLASTIC SYNDROMES (MDS) No dispute reported 06/30/2026 753392961
Principal investigator 1 AbbVie Inc. $431.25 12/16/2020 Non-covered Recipient Entity
DCAM OUTPATIENT PHARMACY
M15-522 No dispute reported 06/30/2026 721201093
Principal investigator 1 AbbVie Inc. $12,031.25 12/15/2020 Non-covered Recipient Entity
DCAM OUTPATIENT PHARMACY
M15-531 No dispute reported 06/30/2026 721200559
Principal investigator 1 AbbVie Inc. $1,000.00 12/09/2020 Non-covered Recipient Entity
DCAM OUTPATIENT PHARMACY
M15-531 No dispute reported 06/30/2026 721200179
Principal investigator 1 AbbVie Inc. $5,843.75 12/03/2020 Non-covered Recipient Entity
DCAM OUTPATIENT PHARMACY
A18-877 No dispute reported 06/30/2026 721199311
Principal investigator 1 AbbVie Inc. $19,922.99 12/01/2020 Non-covered Recipient Entity
DCAM OUTPATIENT PHARMACY
M15-531 No dispute reported 06/30/2026 721198595
Principal investigator 1 AbbVie Inc. $5,500.00 11/23/2020 Non-covered Recipient Entity
DCAM OUTPATIENT PHARMACY
M16-415 No dispute reported 06/30/2026 721196419
Principal investigator 1 Otsuka Pharmaceutical Co., Ltd. $5,250.00 11/19/2020 Non-covered Recipient Entity
THE UNIVERSITY OF CHICAGO
AN OPEN-LABEL, MULTICENTER, EXTENSION STUDY FOR SUBJECTS WHO PARTICIPATED IN PRIOR CLINICAL STUDIES OF ASTX727 (STANDARD DOSE) No dispute reported 06/30/2026 753392957
Principal investigator 1 Incyte Corporation $1,250.00 11/18/2020 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
A Phase 2, Open Label, Monotherapy, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With Myeloid/Lymphoid Neoplasms With FGFR1 Rearrangement No dispute reported 06/30/2026 744307879
Principal investigator 1 Incyte Corporation $4,000.00 11/18/2020 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
A Phase 2, Open Label, Monotherapy, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With Myeloid/Lymphoid Neoplasms With FGFR1 Rearrangement No dispute reported 06/30/2026 744307881
Principal investigator 1 AbbVie Inc. $500.00 11/12/2020 Non-covered Recipient Entity
DCAM OUTPATIENT PHARMACY
M16-415 No dispute reported 06/30/2026 721195127
Principal investigator 1 AbbVie Inc. $19,668.48 11/03/2020 Non-covered Recipient Entity
DCAM OUTPATIENT PHARMACY
A18-877 No dispute reported 06/30/2026 721194209
Principal investigator 1 Agios Pharmaceuticals, Inc. $390.00 10/23/2020 Non-covered Recipient Entity
THE UNIVERSITY OF CHICAGO
A Phase I, Multicenter, Open-Label, Safety Study of AG-120 or AG-221 in Combination with Induction Therapy and Consolidation Therapy in Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 and/or IDH2 Mutation No dispute reported 06/30/2026 752074329
Principal investigator 1 AbbVie Inc. $1,531.74 10/21/2020 Non-covered Recipient Entity
DCAM OUTPATIENT PHARMACY
M16-415 No dispute reported 06/30/2026 721191577
Principal investigator 1 Otsuka Pharmaceutical Co., Ltd. $500.00 10/21/2020 Non-covered Recipient Entity
THE UNIVERSITY OF CHICAGO
A PHASE 3, RANDOMIZED, OPEN-LABEL, CORSSOVER STUDY OF ASTX727 (CEDAZURIDINE AND DECITABINE FIXED-DOSE COMBINATION) VERSUS IV DECITABINE IN SUBJECTS WITH MYELODYSPLASTIC SYNDROMES (MDS) AND CHRONIC MYELOMONOCYTIC LEUKEMIA (CMML) No dispute reported 06/30/2026 753392955
Principal investigator 1 AbbVie Inc. $2,000.00 10/19/2020 Non-covered Recipient Entity
DCAM OUTPATIENT PHARMACY
M15-522 No dispute reported 06/30/2026 721191441
Principal investigator 1 AbbVie Inc. $9,704.24 10/16/2020 Non-covered Recipient Entity
DCAM OUTPATIENT PHARMACY
M15-531 No dispute reported 06/30/2026 721191365
Principal investigator 1 AbbVie Inc. $34,062.99 10/05/2020 Non-covered Recipient Entity
DCAM OUTPATIENT PHARMACY
M14-546 No dispute reported 06/30/2026 721190043
Principal investigator 1 AbbVie Inc. $18,109.24 09/30/2020 Non-covered Recipient Entity
DCAM OUTPATIENT PHARMACY
M16-415 No dispute reported 06/30/2026 721188071
Principal investigator 1 AbbVie Inc. $9,104.24 09/28/2020 Non-covered Recipient Entity
DCAM OUTPATIENT PHARMACY
M15-531 No dispute reported 06/30/2026 721187189
Principal investigator 1 AbbVie Inc. $1,000.00 09/09/2020 Non-covered Recipient Entity
DCAM OUTPATIENT PHARMACY
M15-531 No dispute reported 06/30/2026 721185559
Principal investigator 1 AbbVie Inc. $3,936.00 08/27/2020 Non-covered Recipient Entity
DCAM OUTPATIENT PHARMACY
A18-877 No dispute reported 06/30/2026 721182491
Principal investigator 1 AbbVie Inc. $52,500.00 08/24/2020 Non-covered Recipient Entity
DCAM OUTPATIENT PHARMACY
M15-522 No dispute reported 06/30/2026 721182049
Principal investigator 1 AbbVie Inc. $5,500.00 08/18/2020 Non-covered Recipient Entity
DCAM OUTPATIENT PHARMACY
M16-109 No dispute reported 06/30/2026 721181187
Principal investigator 1 AbbVie Inc. $5,500.00 08/18/2020 Non-covered Recipient Entity
DCAM OUTPATIENT PHARMACY
M16-415 No dispute reported 06/30/2026 721181307
Principal investigator 1 AbbVie Inc. $293.75 08/18/2020 Non-covered Recipient Entity
DCAM OUTPATIENT PHARMACY
M16-415 No dispute reported 06/30/2026 721181309
Principal investigator 1 AbbVie Inc. $1,000.00 08/17/2020 Non-covered Recipient Entity
DCAM OUTPATIENT PHARMACY
M16-415 No dispute reported 06/30/2026 721180999
Principal investigator 1 AbbVie Inc. $4,500.00 08/17/2020 Non-covered Recipient Entity
DCAM OUTPATIENT PHARMACY
M14-546 No dispute reported 06/30/2026 721181145
Principal investigator 1 Otsuka Pharmaceutical Co., Ltd. $500.00 08/14/2020 Non-covered Recipient Entity
THE UNIVERSITY OF CHICAGO
A PHASE 3, RANDOMIZED, OPEN-LABEL, CORSSOVER STUDY OF ASTX727 (CEDAZURIDINE AND DECITABINE FIXED-DOSE COMBINATION) VERSUS IV DECITABINE IN SUBJECTS WITH MYELODYSPLASTIC SYNDROMES (MDS) AND CHRONIC MYELOMONOCYTIC LEUKEMIA (CMML) No dispute reported 06/30/2026 753392951
Principal investigator 1 AbbVie Inc. $9,187.50 08/13/2020 Non-covered Recipient Entity
DCAM OUTPATIENT PHARMACY
A18-877 No dispute reported 06/30/2026 721180731
Principal investigator 1 AbbVie Inc. $59,531.88 08/13/2020 Non-covered Recipient Entity
DCAM OUTPATIENT PHARMACY
A18-877 No dispute reported 06/30/2026 721180733
Principal investigator 1 AbbVie Inc. $4,593.75 08/13/2020 Non-covered Recipient Entity
DCAM OUTPATIENT PHARMACY
A18-877 No dispute reported 06/30/2026 721180735
Principal investigator 1 Gilead Sciences, Inc. $2,215.00 08/03/2020 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
A Phase 3, Randomized, Double-blind Active-controlled Study Evaluating Momelotinib vs. Ruxolitinib in Subjects with Primary Myelofibrosis (PMF) or Post-Polycythemia Vera or Post- Essential Thrombocythemia Myelofibrosis (Post-PV/ET MF) No dispute reported 06/30/2026 742097811
Principal investigator 1 Otsuka Pharmaceutical Co., Ltd. $12,506.25 08/01/2020 Non-covered Recipient Entity
THE UNIVERSITY OF CHICAGO
A PHASE1-2 PHARMACOKINETIC GUIDED DOSE-ESCALATION AND DOSE-CONFIRMATION STUDY OF ASTX727, A COMBINATION OF THE ORAL CYTIDINE DEAMINASE INHIBITOR (CDAI) E7727 WITH ORAL DECITABINE IN SUBJECTS WITH MYELODYSPLASTIC SYNDROMES (MDS) No dispute reported 06/30/2026 753392947
Principal investigator 1 Otsuka Pharmaceutical Co., Ltd. $5,250.00 07/29/2020 Non-covered Recipient Entity
THE UNIVERSITY OF CHICAGO
A PHASE 3, RANDOMIZED, OPEN-LABEL, CORSSOVER STUDY OF ASTX727 (CEDAZURIDINE AND DECITABINE FIXED-DOSE COMBINATION) VERSUS IV DECITABINE IN SUBJECTS WITH MYELODYSPLASTIC SYNDROMES (MDS) AND CHRONIC MYELOMONOCYTIC LEUKEMIA (CMML) No dispute reported 06/30/2026 753392945
Principal investigator 1 AbbVie Inc. $768.75 06/29/2020 Non-covered Recipient Entity
DCAM OUTPATIENT PHARMACY
M15-522 No dispute reported 06/30/2026 721172593
Principal investigator 1 AbbVie Inc. $1,475.28 06/25/2020 Non-covered Recipient Entity
DCAM OUTPATIENT PHARMACY
A18-877 No dispute reported 06/30/2026 721172287
Principal investigator 1 AbbVie Inc. $1,000.00 06/23/2020 Non-covered Recipient Entity
DCAM OUTPATIENT PHARMACY
M16-415 No dispute reported 06/30/2026 721172005
Principal investigator 1 AbbVie Inc. $4,375.00 06/22/2020 Non-covered Recipient Entity
DCAM OUTPATIENT PHARMACY
M15-531 No dispute reported 06/30/2026 721171829
Principal investigator 1 AstraZeneca Pharmaceuticals LP $19,780.33 06/16/2020 Non-covered Recipient Entity
The University Of Chicago
Phase I Study of MEK Inhibitor Selumentinib in Combination with Azacitidine in Patients with Higher Risk Chronic Myeloid Neoplasia- MDS, MDS MPNs and Myelofibrosis No dispute reported 06/30/2026 736748555
Principal investigator 1 AbbVie Inc. $13,125.00 06/04/2020 Non-covered Recipient Entity
DCAM OUTPATIENT PHARMACY
M15-531 No dispute reported 06/30/2026 721170451
Principal investigator 1 AbbVie Inc. $3,562.50 05/29/2020 Non-covered Recipient Entity
DCAM OUTPATIENT PHARMACY
M15-531 No dispute reported 06/30/2026 721168913
Principal investigator 1 AbbVie Inc. $44,875.00 05/15/2020 Non-covered Recipient Entity
DCAM OUTPATIENT PHARMACY
M15-531 No dispute reported 06/30/2026 721166123
Principal investigator 1 Celgene Corporation $36,125.00 05/06/2020 Non-covered Recipient Entity
University Of Chicago Medical Center
A Phase 3b, Multicenter, Single-Arm, Open-Label Efficacy & Safety Study of Fedratinib in Subjects w/ DIPSS-Intermediate or High-Risk PMF, post-PV MF, or post-ET MF & Previously Treated w/ Ruxolitinib incl. Sub-study w/ concomitant Luspatercept for anemia No dispute reported 06/30/2026 736446161
Principal investigator 1 AbbVie Inc. $7,227.50 05/04/2020 Non-covered Recipient Entity
DCAM OUTPATIENT PHARMACY
M16-415 No dispute reported 06/30/2026 721164943
Principal investigator 1 Otsuka Pharmaceutical Co., Ltd. $33,715.00 04/22/2020 Non-covered Recipient Entity
THE UNIVERSITY OF CHICAGO
A RANDOMIZED, OPEN-LABEL, PHASE 1-2 STUDY OF ASTX727 LOW DOSE (ASTX727 LD) EXTENDED SCHEDULE IN SUBJECTS WITH LOWER RISK (IPSS LOW OR INTERMEDIATE-1) MYELODYSPLASTIC SYNDROMES (MDS) No dispute reported 06/30/2026 753392939
Principal investigator 1 AbbVie Inc. $500.00 04/21/2020 Non-covered Recipient Entity
DCAM OUTPATIENT PHARMACY
M15-531 No dispute reported 06/30/2026 721161575
Principal investigator 1 Incyte Corporation $4,000.00 04/17/2020 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
A Phase 2, Open Label, Monotherapy, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With Myeloid/Lymphoid Neoplasms With FGFR1 Rearrangement No dispute reported 06/30/2026 744307829
Principal investigator 1 Incyte Corporation $1,250.00 04/17/2020 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
A Phase 2, Open Label, Monotherapy, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With Myeloid/Lymphoid Neoplasms With FGFR1 Rearrangement No dispute reported 06/30/2026 744307831
Principal investigator 1 AbbVie Inc. $39,612.50 04/16/2020 Non-covered Recipient Entity
DCAM OUTPATIENT PHARMACY
M15-522 No dispute reported 06/30/2026 721160977
Principal investigator 1 Otsuka Pharmaceutical Co., Ltd. $1,750.00 04/08/2020 Non-covered Recipient Entity
THE UNIVERSITY OF CHICAGO
A PHASE 3, RANDOMIZED, OPEN-LABEL, CORSSOVER STUDY OF ASTX727 (CEDAZURIDINE AND DECITABINE FIXED-DOSE COMBINATION) VERSUS IV DECITABINE IN SUBJECTS WITH MYELODYSPLASTIC SYNDROMES (MDS) AND CHRONIC MYELOMONOCYTIC LEUKEMIA (CMML) No dispute reported 06/30/2026 753392929
Principal investigator 1 Otsuka Pharmaceutical Co., Ltd. $5,000.00 04/08/2020 Non-covered Recipient Entity
THE UNIVERSITY OF CHICAGO
A PHASE 3, RANDOMIZED, OPEN-LABEL, CORSSOVER STUDY OF ASTX727 (CEDAZURIDINE AND DECITABINE FIXED-DOSE COMBINATION) VERSUS IV DECITABINE IN SUBJECTS WITH MYELODYSPLASTIC SYNDROMES (MDS) AND CHRONIC MYELOMONOCYTIC LEUKEMIA (CMML) No dispute reported 06/30/2026 753392931
Principal investigator 1 Otsuka Pharmaceutical Co., Ltd. $500.00 04/08/2020 Non-covered Recipient Entity
THE UNIVERSITY OF CHICAGO
A PHASE 3, RANDOMIZED, OPEN-LABEL, CORSSOVER STUDY OF ASTX727 (CEDAZURIDINE AND DECITABINE FIXED-DOSE COMBINATION) VERSUS IV DECITABINE IN SUBJECTS WITH MYELODYSPLASTIC SYNDROMES (MDS) AND CHRONIC MYELOMONOCYTIC LEUKEMIA (CMML) No dispute reported 06/30/2026 753392933
Principal investigator 1 AbbVie Inc. $8,195.20 04/06/2020 Non-covered Recipient Entity
DCAM OUTPATIENT PHARMACY
A18-877 No dispute reported 06/30/2026 721160097
Principal investigator 1 AbbVie Inc. $500.00 04/06/2020 Non-covered Recipient Entity
DCAM OUTPATIENT PHARMACY
M15-522 No dispute reported 06/30/2026 721160107
Principal investigator 1 AbbVie Inc. $10,962.99 03/31/2020 Non-covered Recipient Entity
DCAM OUTPATIENT PHARMACY
M16-415 No dispute reported 06/30/2026 721159175
Principal investigator 1 AbbVie Inc. $9,900.00 03/27/2020 Non-covered Recipient Entity
DCAM OUTPATIENT PHARMACY
M15-531 No dispute reported 06/30/2026 721157393
Principal investigator 1 AbbVie Inc. $1,937.50 03/25/2020 Non-covered Recipient Entity
DCAM OUTPATIENT PHARMACY
M15-522 No dispute reported 06/30/2026 721156997
Principal investigator 1 AbbVie Inc. $6,481.25 03/04/2020 Non-covered Recipient Entity
DCAM OUTPATIENT PHARMACY
M15-531 No dispute reported 06/30/2026 721154433
Principal investigator 1 Celgene Corporation $14,361.88 02/26/2020 Non-covered Recipient Entity
The University Of Chicago Medicine
PhII CC-486 mono and combo with Durvalumab in MDS Post HMA failures ) No dispute reported 06/30/2026 736443565
Principal investigator 1 AbbVie Inc. $2,300.00 02/20/2020 Non-covered Recipient Entity
DCAM OUTPATIENT PHARMACY
M15-522 No dispute reported 06/30/2026 721151641
Principal investigator 1 AbbVie Inc. $2,622.72 02/13/2020 Non-covered Recipient Entity
DCAM OUTPATIENT PHARMACY
A18-877 No dispute reported 06/30/2026 721150547
Principal investigator 1 AbbVie Inc. $819.52 02/13/2020 Non-covered Recipient Entity
DCAM OUTPATIENT PHARMACY
A18-877 No dispute reported 06/30/2026 721150549
Principal investigator 1 AbbVie Inc. $1,639.04 02/13/2020 Non-covered Recipient Entity
DCAM OUTPATIENT PHARMACY
A18-877 No dispute reported 06/30/2026 721150551
Principal investigator 1 AbbVie Inc. $3,278.08 02/13/2020 Non-covered Recipient Entity
DCAM OUTPATIENT PHARMACY
A18-877 No dispute reported 06/30/2026 721150553
Principal investigator 1 Otsuka Pharmaceutical Co., Ltd. $500.00 02/06/2020 Non-covered Recipient Entity
THE UNIVERSITY OF CHICAGO
A PHASE 3, RANDOMIZED, OPEN-LABEL, CORSSOVER STUDY OF ASTX727 (CEDAZURIDINE AND DECITABINE FIXED-DOSE COMBINATION) VERSUS IV DECITABINE IN SUBJECTS WITH MYELODYSPLASTIC SYNDROMES (MDS) AND CHRONIC MYELOMONOCYTIC LEUKEMIA (CMML) No dispute reported 06/30/2026 753392925
Principal investigator 1 AbbVie Inc. $500.00 01/31/2020 Non-covered Recipient Entity
DCAM OUTPATIENT PHARMACY
M16-415 No dispute reported 06/30/2026 721148687
Principal investigator 1 AbbVie Inc. $6,012.50 01/31/2020 Non-covered Recipient Entity
DCAM OUTPATIENT PHARMACY
M15-531 No dispute reported 06/30/2026 721148881
Principal investigator 1 AbbVie Inc. $500.00 01/30/2020 Non-covered Recipient Entity
DCAM OUTPATIENT PHARMACY
M15-531 No dispute reported 06/30/2026 721148555
Principal investigator 1 AbbVie Inc. $20,530.49 01/29/2020 Non-covered Recipient Entity
DCAM OUTPATIENT PHARMACY
M16-415 No dispute reported 06/30/2026 721147441
Recipient AbbVie Inc. $3,300.00 01/27/2020 Covered Recipient Physician Not supplied No dispute reported 06/30/2026 721142825
Principal investigator 1 AbbVie Inc. $2,687.50 01/27/2020 Non-covered Recipient Entity
DCAM OUTPATIENT PHARMACY
M15-522 No dispute reported 06/30/2026 721147199
Principal investigator 1 Otsuka Pharmaceutical Co., Ltd. $1,366.88 01/24/2020 Non-covered Recipient Entity
THE UNIVERSITY OF CHICAGO
A PHASE 3, RANDOMIZED, OPEN-LABEL, CORSSOVER STUDY OF ASTX727 (CEDAZURIDINE AND DECITABINE FIXED-DOSE COMBINATION) VERSUS IV DECITABINE IN SUBJECTS WITH MYELODYSPLASTIC SYNDROMES (MDS) AND CHRONIC MYELOMONOCYTIC LEUKEMIA (CMML) No dispute reported 06/30/2026 753392921
Principal investigator 1 Celgene Corporation $7,496.28 01/21/2020 Non-covered Recipient Entity
The University Of Chicago Medicine
Phase IIA AG-221-AML-005 (BMS Study Number: CA067-P12) No dispute reported 06/30/2026 736443433
Principal investigator 1 Incyte Corporation $45.60 01/09/2020 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
A Phase 2, Open Label, Monotherapy, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With Myeloid/Lymphoid Neoplasms With FGFR1 Rearrangement No dispute reported 06/30/2026 744307675
Principal investigator 1 Incyte Corporation $28.65 01/09/2020 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
A Phase 2, Open Label, Monotherapy, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With Myeloid/Lymphoid Neoplasms With FGFR1 Rearrangement No dispute reported 06/30/2026 744307677
Principal investigator 1 Incyte Corporation $76.00 01/09/2020 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
A Phase 2, Open Label, Monotherapy, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With Myeloid/Lymphoid Neoplasms With FGFR1 Rearrangement No dispute reported 06/30/2026 744307679
Principal investigator 1 Incyte Corporation $47.75 01/09/2020 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
A Phase 2, Open Label, Monotherapy, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With Myeloid/Lymphoid Neoplasms With FGFR1 Rearrangement No dispute reported 06/30/2026 744307681
Principal investigator 1 Incyte Corporation $7.60 01/09/2020 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
A Phase 2, Open Label, Monotherapy, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With Myeloid/Lymphoid Neoplasms With FGFR1 Rearrangement No dispute reported 06/30/2026 744307683
Principal investigator 1 Incyte Corporation $28.65 01/09/2020 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
A Phase 2, Open Label, Monotherapy, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With Myeloid/Lymphoid Neoplasms With FGFR1 Rearrangement No dispute reported 06/30/2026 744307717
Principal investigator 1 Incyte Corporation $28.65 01/09/2020 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
A Phase 2, Open Label, Monotherapy, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With Myeloid/Lymphoid Neoplasms With FGFR1 Rearrangement No dispute reported 06/30/2026 744307719
Principal investigator 1 Incyte Corporation $45.60 01/09/2020 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
A Phase 2, Open Label, Monotherapy, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With Myeloid/Lymphoid Neoplasms With FGFR1 Rearrangement No dispute reported 06/30/2026 744307721
Principal investigator 1 Incyte Corporation $76.00 01/09/2020 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
A Phase 2, Open Label, Monotherapy, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With Myeloid/Lymphoid Neoplasms With FGFR1 Rearrangement No dispute reported 06/30/2026 744307723
Principal investigator 1 AbbVie Inc. $7,500.00 01/07/2020 Non-covered Recipient Entity
DCAM OUTPATIENT PHARMACY
M14-546 No dispute reported 06/30/2026 721144691
Principal investigator 1 AbbVie Inc. $14,537.50 01/02/2020 Non-covered Recipient Entity
DCAM OUTPATIENT PHARMACY
M15-531 No dispute reported 06/30/2026 721143975